Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Sateesh Kesari

Advanced Heart Failure and Transplant Cardiology Cincinnati, OH Medical Doctor

NPI 1396910824 CMS profile 62907

10506A Montgomery Rd, Cincinnati, OH 45242

Open in the dashboard

General payments

$100,651

388 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$22,500 paid to institutions, not to them · program year 2024

Through program year 2025, Sateesh Kesari of Cincinnati, OH is reported in the CMS Open Payments database as having received $100,651 across 388 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $22,500 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 86th percentile of Advanced Heart Failure and Transplant Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $56,263 92
2024 General $34,214 85
2023 General $6,159 96
2022 General $2,054 61
2021 General $1,022 37
2020 General $112 8
2019 General $827 9

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sateesh Kesari
  • Advanced Heart Failure and Transplant Cardiology median
  • Middle half of Advanced Heart Failure and Transplant Cardiology
  • National median

In program year 2025, general payments to Sateesh Kesari were reported at $56,263. Among 967 Advanced Heart Failure and Transplant Cardiology profiles paid that year, the median was $1,024 and the middle half received between $289 and $6,890.

Show as a table
Year Sateesh Kesari Advanced Heart Failure and Transplant Cardiology median Middle half National median
2019 $827 $863 $224–$4,562 $163
2020 $112 $452 $122–$3,992 $114
2021 $1,022 $550 $159–$3,571 $132
2022 $2,054 $729 $221–$4,357 $149
2023 $6,159 $1,002 $309–$5,827 $160
2024 $34,214 $931 $273–$5,204 $164
2025 $56,263 $1,024 $289–$6,890 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. E.R. Squibb & Sons, L.L.C. $37,641 42 payments
  2. Alnylam Pharmaceuticals Inc. $30,270 34 payments
  3. Pfizer Inc. $15,565 24 payments
  4. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $7,814 22 payments
  5. Abbott Laboratories $3,221 69 payments
  6. Abiomed $1,646 16 payments
  7. Medtronic Vascular, Inc. $531 7 payments
  8. Merck Sharp & Dohme Corporation $523 28 payments
  9. Novartis Pharmaceuticals Corporation $473 36 payments
  10. CVRx, Inc. $282 8 payments
  11. Other $2,688 102 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $52,933 14 payments
  2. Grant $15,000 1 payment
  3. Travel and Lodging $11,966 37 payments
  4. Food and Beverage $10,385 324 payments
  5. Consulting Fee $10,110 4 payments
  6. Education $258 8 payments
Products named General payments · program years 2019–2025
  1. CAMZYOS $33,131 31 payments
  2. AMVUTTRA $30,010 21 payments
  3. LifeVest $7,814 22 payments
  4. CARDIOMEMS $1,838 45 payments
  5. Impella $641 5 payments
  6. VERQUVO $518 30 payments
  7. THORATEC HEARTMATE 3 LVAS IMPLANT KIT $455 9 payments
  8. CardioMEMS HF System $350 7 payments
  9. Barostim Neo System $282 8 payments
  10. VYNDAQEL $260 13 payments
  11. Other $4,773 209 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 24 drugs

Part D claims

964

Median for Cardiology: 2,533

Drug cost

$1,448,329

Median for Cardiology: $485,213

Branded share of claims

39.7%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Camzyos Mavacamten Brand 94 $771,513
Opsumit Macitentan Brand 16 $203,316
Adempas Riociguat Brand 15 $195,940
Orenitram Er Treprostinil Diolamine Brand 15 $107,474
Entresto Sacubitril/Valsartan Brand 101 $80,179
Jardiance Empagliflozin Brand 55 $39,049
Farxiga Dapagliflozin Propanediol Brand 49 $33,540
Eliquis Apixaban Brand 13 $12,079
Eplerenone Generic 15 $1,141
Metoprolol Succinate Generic 138 $1,141

The 10 drugs with the highest cost, of 24 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 35 billing codes

Paid by Medicare

$97,097

Medicare's payments for the services billed

Medicare patients

207

Average age 74

Services billed

1,226

74 women, 133 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Heart failure 75%
Ischemic heart disease 75%
Atrial fibrillation 66%
Chronic kidney disease 60%
Diabetes 50%
Arthritis 43%
COPD 30%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 24 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
CAMZYOS
  • E.R. Squibb & Sons, L.L.C. $17,139
$17,139 94 —
AMVUTTRA
  • Alnylam Pharmaceuticals Inc. $125
$125 — —
VYNDAQEL
  • PFIZER INC. $114
$114 — —
VERQUVO
  • Merck Sharp & Dohme Corporation $113
$113 — —
ENTRESTO
  • Novartis Pharmaceuticals Corporation $76
$76 101 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 24 in the dashboard with a free account

Records

388 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Advanced Heart Failure and Transplant Cardiology in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record